-
Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials
•
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried human rabies vaccine, developed using human diploid/MRC-5 cells. This innovative vaccine utilizes human diploid cells, which are widely recognized in international…
-
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its human anti-tetanus toxin monoclonal antibody (mAb) A82/B86 injection combination preparation. This innovative treatment is designed as a prophylactic against tetanus. Tetanus, a serious bacterial…
-
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
•
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805 million (USD 110 million) in the production of 10 million annual doses of its influenza virus split vaccine (BK-01 adjuvant). This substantial investment includes RMB 659 million for industrialization and RMB 146 million for operational…
